Heart Failure

Investigators found that a plant-based diet was associated with a 41% reduction in heart failure risk, while a “southern” diet heavy in fried food, added fats, and eggs was associated with a 72% increase in risk.

Investigators found that participants who never ate breakfast were 87% more likely to die from cardiovascular disease and stroke than those who ate breakfast every day.

Study finds that, despite the creation of the Hospital Readmissions Reduction Program, US and Canada saw similar declines in HF readmission rates.

Ivabradine can be an important tool to lower heart rates in patients with heart failure, but a new study finds usage rates are low when physicians aren’t proactive about initiating the therapy.

Investigators found readmission risk was 4 times greater in patients with stays of 2 days or less.

A study of patients recommended for statin therapy under ACC/AHA guidelines, but not taking any, found that 59.2% reported never being offered a statin.

A new cohort assessment shows white and African American men both have a lifetime hypertension risk of more than 80%.

Investigators observed a 22% and 20% increased risk of heart failure during the 2 most severe influenza seasons.

How the PIONEER-HF and PARADIGM-HF trials have focused on varied, but realistic heart failure patients.

A year-long outpatient care study showed that patients with type 2 diabetes and comorbid cardiovascular disease are 5 times as likely to visit a cardiologist.

A new long-term data analysis reports that about 50% of patients adhere to the critcal therapy after just 1 year, and the rate continues to drop after that.

The breakthrough device is indicated to improve 6-minute walk distance for certain patients with chronic heart failure.

With cardiovascular drug classes inhibitors owning discussion, how will recent or upcoming guideline updates address their use alongside lifestyle management?

Progress in invasive measures for cardiovascular conditions has allowed clinicians the ability to venture into new ground.

An extension of the study showed sacubitril/valsartan's benefit as an initial hospitalized heart failure therapy.

How alirocumab fared for patients with polyvascular disease in a subset of the major clinical trial.

Heart disease is the greatest cause of death in women, and Wood believes female patients would better from a multidisciplinary approach.

Among participants of the EMPA-REG OUTCOME trial who experienced heart failure, empagliflozin was associated with lower rates of short-term re-hospitalization and death.

A 5000-plus patient study found that about 80% of young women have never been administered a lipid test.

The rate of heart attacks among patients under 40 years old has been increasing by 2% annually for the past decade.

Now that SGLT-2 inhibitors have reached the market, how will clinicians compare their benefits in patients?

How advancing stent therapy options have come to bridge the gap between improving and elongating a patient's life.

How the effective cardiovascular drug class have reach a state of impending head-to-head trials.

A system which rewards hospitals based on their patient readmission rates may not be considering other factors of care.

A prospective study found that daily dapagliflozin significantly improved mitral flow, left ventricular mass index, and left atrial volume index after 6 months of treatment.